Publications by authors named "E Vrdoljak"
Associations between PIK3CA Mutations and Disease Free Survival in Patients with HR+, HER2- Tumors Treated with Adjuvant Hormonal Therapy: A Real-World Study in Croatia.
Breast J
January 2025
Article Synopsis
- The study focuses on the challenges of managing disease recurrence in early-stage hormone receptor-positive (HR+), HER2-negative breast cancer due to its biological complexity and the presence of PIK3CA mutations.
- Approximately 30-40% of advanced HR+/HER2- breast cancer patients have PIK3CA mutations, which are linked to poor prognosis by activating pathways that promote cell growth.
- The research found that patients with the PIK3CA mutation, particularly the H1047 variant, had a lower risk of disease recurrence compared to those without the mutation, suggesting its potential as a biomarker for personalized treatment strategies.
Background: Recent evidence brought by novel anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugates is leading to significant changes in HER2-negative breast cancer (BC) best practices. A new targetable category termed 'HER2-low' has been identified in tumors previously classified as 'HER2-negative'. Daily practice in pathology and medical oncology is expected to align to current recommendations, but patient access to novel anticancer drugs across geographies might be impeded due to local challenges.
View Article and Find Full Text PDFThe aim of the study was to conduct a retrospective database analysis to understand the current treatment patterns and outcomes to plan potential improvements in therapy delivery and patient selection. The electronic patient medical records of 225 patients with advanced gastric and esophagogastric adenocarcinoma treated at two Croatian high-volume tertiary centers from January 2018 to December 2021 were analyzed. Patients ineligible for chemotherapy (66 of 291, 22.
View Article and Find Full Text PDFIntroduction: There are no recommended biomarkers to identify patients with refractory metastatic colorectal cancer (mCRC) who would benefit the most from trifluridine/tipiracil (TTP). The exploratory analysis of the RECOURSE trial revealed that patients with low tumor burden and indolent disease derive greater benefit in terms of both progression-free survival (PFS) and overall survival (OS). Nevertheless, the final answer on the TTP real impact on the well-being of patients with late-stage mCRC will come from real-world data.
View Article and Find Full Text PDF